Bin1 Antibodies for IBD Therapy: Is Permeability the Answer BAR None?

Excerpt

The inflammatory bowel diseases (IBD) ulcerative colitis (UC) and Crohn’s disease (CD), of unknown etiology despite being extensively investigated over the last few decades, share important common pathogenic mechanisms. The interaction of genetic predisposing factors, exogenous and endogenous triggers, and modifying mediators induce inflammation and immune-mediated tissue injury. In UC, with inflammation mostly limited to the large bowel, acute and chronic inflammatory cells infiltrate the lamina propria with the formation of crypt microabscesses [1]. Recent diagnostic and therapeutic advances have been based on the increasing knowledge of the interplay between the cellular components and soluble mediators in the gut mucosa, combined with therapeutic strategies that target immunological mechanisms [2]. …